Compare INBK & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | INBK | OBIO |
|---|---|---|
| Founded | 1999 | 2017 |
| Country | United States | United States |
| Employees | 355 | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 231.2M | 238.9M |
| IPO Year | N/A | 2020 |
| Metric | INBK | OBIO |
|---|---|---|
| Price | $26.64 | $3.98 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $23.25 | $14.25 |
| AVG Volume (30 Days) | 26.8K | ★ 201.3K |
| Earning Date | 04-30-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.06% | N/A |
| EPS Growth | N/A | ★ 33.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $33,482,000.00 |
| Revenue This Year | $279.34 | N/A |
| Revenue Next Year | $12.97 | $12.43 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1169.22 |
| 52 Week Low | $17.05 | $2.20 |
| 52 Week High | $28.88 | $5.42 |
| Indicator | INBK | OBIO |
|---|---|---|
| Relative Strength Index (RSI) | 59.17 | 54.66 |
| Support Level | $25.23 | $3.77 |
| Resistance Level | $28.88 | $4.18 |
| Average True Range (ATR) | 0.91 | 0.15 |
| MACD | -0.02 | 0.03 |
| Stochastic Oscillator | 100.00 | 95.42 |
First Internet Bancorp is a bank holding company. Through its subsidiaries, it provides commercial real estate (CRE) lending, including nationwide single tenant lease financing and commercial and industrial (C&I) lending, including business banking or treasury management services. The company offers its products and services through the internet and does not have any branches. With operations organized into a single segment called the Commercial Banking segment, it also provides retail banking services.
Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality. It has one reportable segment, which consists of the development of clinical and preclinical product candidates through risk-reward sharing partnerships with medical device companies.